Biocon Biologics Acquires Pfizer’s Research Facility to Expand its Research and Development Footprint

Biocon Biologics Acquires Pfizer’s Research Facility to Expand its R&D Footprints

Shots:

  • Biocon Biologics has acquired Pfizer’s 60,000 sq. ft state-of-the-art, bench to pilot scale R&D facility at TICEL Bio Park in Chennai, India
  • The focus of the acquisition is to expand Biocon’s R&D capabilities and to accelerate the development of its biosimilars from lab to pilot scale, addressing the needs of patients globally
  • The facility will house an early stage R&D center including pilot-scale R&D unit, equipped with cell line development, drug substance process development from bench scale to 400L scale bioreactors, drug product formulation laboratories, analytical R&D laboratories with 250+ scientists

Click here to­ read full press release/ article | Ref: Biocon | Image: Twitter